# RareKids-CAN Releases Second White Paper Advocating for Reforms to the Special Access Program

> The RARE-SAP white paper advocates for the modernization of Health Canada’s Special Access Program.

Shaped by patients, families, healthcare professionals, researchers and policy experts from the rare disease community, RARE-SAP is already making an impact in Parliament 

RareKids-CAN and our partner the SickKids Child Health Policy Accelerator are delighted to announce the release of our second policy white paper, RARE-SAP: Reforming the Special Access Program to Improve Access to Lifesaving Treatments for Critically Ill Children. It is a paper shaped by the lived experience of patients, families and clinicians, whose voices guided its direction from the start.

The paper advocates for the modernization of Health Canada’s Special Access Program (SAP). Clinicians use this pathway to request access to drugs that are not commercially available in Canada in emergency situations for the treatment of serious or life-threatening conditions. Every year, hundreds of children with rare diseases rely on the SAP to access life-sustaining and life-enhancing treatments.  

"One of the most meaningful parts of the RARE-SAP journey has been seeing an issue raised by patients, families and healthcare professionals grow into a national policy initiative," explains Breanne Stewart, Network Director, RareKids-CAN. "We started by listening to the challenges people were experiencing in accessing critically needed treatments and asking what could be changed. From there, we brought together the right healthcare, patient, research and policy expertise to develop a practical path forward."

"To now see those recommendations informing conversations in Parliament is an important example of how RareKids-CAN can help move from lived experience to meaningful system change."

What the paper recommends

Drawing on the experience of Australia and France, RARE-SAP calls on Health Canada to:

Eliminate the “fail-first” requirement that compels patients to try potentially less safe or less effective on-market therapies before accessing the optimal treatment through the SAP.

Develop streamlined, patient-centred pathways that facilitate access to essential therapies, including:

For therapies with a well-established history of use: Create a list of non-marketed therapies that are supported by robust clinical data, a history of safe and effective use, and established Canadian clinical practice, that are pre-approved for importation and use under a modernized SAP.

For therapies not included on the pre-approved list: Develop flexible and permissive access pathways that facilitate the importation and use of treatments with emerging evidence of safety and efficacy through a revised case-by-case special access framework with appropriate regulatory oversight.

Develop a modern, efficient, and transparent system that reduces unnecessary administrative burden and increases clarity for practitioners.

Together, these reforms would reduce unnecessary regulatory burdens and administrative barriers, and accelerate access to treatments available in other trusted jurisdictions, without compromising the rigorous safety standards that define Canada’s healthcare system.

A paper built with community and expertise

The need for SAP reform was first identified by members of the RareKids-CAN community at our 2025 Annual Meeting. During a session on regulatory barriers to rare disease care, families, healthcare professionals and researchers described the challenges of accessing treatments through the SAP and the absence of flexible, risk-based pathways to more novel therapies.

RareKids-CAN and the SickKids Child Health Policy Accelerator took up this call and established the Community of Practice on Advancing Pediatric Regulatory Reform to provide further expert advice and co-develop policy recommendations. Clinicians, researchers and policy experts from over 25 pediatric hospitals, research networks, policy organizations and patient advocacy organizations contributed to the development of the white paper.

We extend our heartfelt thanks to every healthcare professional, researcher and policy expert who generously gave their time and knowledge to shape these recommendations. It is their experience, expertise and willingness to collaborate across institutions and disciplines that make these recommendations credible and practical options for policy reform.

Led by lived experience

Parents and families of children with rare diseases were central to every stage of the policy development process, and this paper would not have been possible without them. During consultations, families told us that being required to “try and fail, or find clinically unsuitable” every on-market option before accessing the most appropriate treatment is a serious barrier to care. Their insight led directly to one of the paper’s central recommendations. Eliminating the “fail-first” requirement is now one of our primary advocacy priorities, demonstrating the critical role of lived experience in shaping advocacy.

Caregivers of a child with a rare disease have also been vital to our advocacy beyond the paper itself. They have travelled to Ottawa for multiple meetings to share their stories with parliamentarians, spoken in national webinars, and written over 480 letters to 165 politicians across nine provinces in support of Bill C-265. We are deeply grateful for their generosity, courage and commitment.

The process of developing the white paper and Bill C-265 shows what's possible when a group of dedicated advocates, with the weight of lived experience and clinical expertise, come together to push for targeted policy reform. Congratulations and thank you to all who have contributed to this process. Any success that comes from this work belongs to you, and we look forward to continuing our advocacy together.

“Advocating for care used to feel lonely and hopeless sometimes; me versus the system I had no power to change," shares Lynn Mendoza, RareKids-CAN family partner and mother to a child with a rare disease.

"Being part of this initiative gave me hope again—a belief that there are people who genuinely care about making the system better, who are willing not only to listen to patient voices but also put in the work needed to address core issues."

"It’s been firsthand proof that patients can be partners, and that our stories matter and can bring about meaningful change.”

Read the RARE-SAP white paper (PDF)
